Elevation Oncology to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Elevation Oncology (Nasdaq: ELEV), an innovative oncology company focused on developing selective cancer therapies for patients with solid tumors and significant unmet medical needs, has announced its participation in two upcoming investor conferences in March 2025.
The company will participate in:
- The TD Cowen 45th Annual Health Care Conference with a fireside chat on Tuesday, March 4, 2025 at 9:10 AM ET in Boston, MA
- The Leerink Global Biopharma Conference with a fireside chat on Tuesday, March 11, 2025 at 8:40 AM ET in Miami, FL
Live webcasts and replays of both fireside chats will be available on the Events page of Elevation Oncology's Investor Relations website at https://investors.elevationoncology.com.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ELEV declined 9.19%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
- TD Cowen 45th Annual Health Care Conference. Fireside chat on Tuesday, March 4, 2025 at 9:10 AM ET in
Boston, MA. - Leerink Global Biopharma Conference. Fireside chat on Tuesday, March 11, 2025 at 8:40 AM ET in
Miami, FL.
A live webcast and replay of the fireside chats will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our ADC expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class, Claudin 18.2 ADC and is currently being evaluated in a Phase 1 trial (NCT05980416) as a monotherapy, and in combinations with dostarlimab or ramucirumab, in patients with advanced, unresectable or metastatic gastric/gastroesophageal adenocarcinoma that express Claudin 18.2. We are also advancing EO-1022, a HER3 ADC for the treatment of patients living with solid tumors that express HER3, through preclinical development. For more information, visit www.ElevationOncology.com.
Elevation Oncology Investor and Media Contact
Gracie Tong
Senior Director, Investor Relations and Corporate Communications
gtong@elevationoncology.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-participate-in-upcoming-investor-conferences-302382527.html
SOURCE Elevation Oncology
FAQ
When will Elevation Oncology (ELEV) present at the TD Cowen Health Care Conference in 2025?
What investor conferences is Elevation Oncology (ELEV) attending in March 2025?
Where can investors watch Elevation Oncology's (ELEV) March 2025 conference presentations?
What is Elevation Oncology's (ELEV) focus in cancer treatment development?
When is Elevation Oncology (ELEV) presenting at the Leerink Global Biopharma Conference?
